Pressurised Metered Dose Inhalers (pMDIs) are vital medical devices, but they are a major source of the inhalation industry’s carbon footprint. Low carbon pMDIs are highly feasible, but facilitating an industry-wide transition is complex. Above all else, as low carbon pMDI production is scaled up, there must be no disruption in the supply of essential therapeutics.
Bespak’s Commercial Director, Simon Gardner, shared his insights with OndrugDelivery on this important topic, delving into the challenges and opportunities involved in rolling out low carbon pMDIs at scale. He further expands on how CDMOs, such as Bespak, can help to facilitate the transition and avoid supply shortages for patients.
